R4D’s Center for Global Health R&D Policy Assessment released its latest draft report, “Can a R&D Tax Credit Expand Investment in Product Development for Global Health?” for public comment.
The draft report considers whether a R&D tax credit would encourage pharmaceutical and biotechnology companies to increase research and development for diseases of the poor. Tax credits are common fiscal incentives that countries across the world use to support private R&D.
The report explores the experiences of past research credits for health like the Orphan Drug Clinical Research Credit and the UK’s Vaccine Research Relief Programme and draws lessons for recently proposed legislation in the U.S. The report identifies pertinent unanswered questions around what drives global health decision-making within firms and discusses the potential impact of a global health credit.
The Center for Global Health R&D Policy Assessment is dedicated to expanding and improving the information used by governments, philanthropists and private investors to make decisions on new ways to drive research and development (R&D) in global health.
To stay informed about our latest work, visit our website www.healthresearchpolicy.org.